VOYAGER PAD: Live Long and Rivaroxaban

Dr. Jessica Carey discusses the VOYAGER PAD trial and antithrombotic management in PAD patients post-revascularization. 0:00-0:40: Intro 0:41-1:46: Introduction of Dr. Jessica Carey 1:47-5:52: VOYAGER PAD Overview 5:53-9:10: Previous management of PAD 9:11-11:18: PAD Interventions 11:19-13:49: Overall thoughts about VOYAGER PAD 13:50-15:19: Antithrombotic management of PAD 15:19-16:01: Closing References: VOYAGER PAD: Bonaca MP, Bauersachs RM,Continue reading “VOYAGER PAD: Live Long and Rivaroxaban”

The Caravaggio Trial: Painting DOACs into the Picture

Guest Dr. Paul Dobesh discusses the Caravaggio trial and DOAC use for VTE management in patients with cancer. 0:00-0:40: Intro0:41-1:35: Introduction of Dr. Paul Dobesh1:36-4:02: Caravaggio trial overview 4:03-7:08: Background of VTE antithrombotic management in cancer 7:09-9:09: Overall thoughts and where apixaban fits9:10-10:42: ADAM-VTE Trial10:43-13:36: Bleeding13:37-14:37: PROBE trial design14:38-15:47: Approach the VTE antithrombotic management inContinue reading “The Caravaggio Trial: Painting DOACs into the Picture”

Popular, I know about POPular TAVI

0:00-0:40: Intro 0:41-1:25: Introduction of Dr. John Lindsley 1:26-5:57: POPular TAVI trial overview 5:58-8:35: Background of TAVI antithrombotic management 8:36-10-43: Intial thoughts about POPular TAVI 10:44-14:53: Study design 14:54- 17:22: Antithrombotic management 17:23-18:06: Closing References POPular TAVI Trial: Nijenhuis VJ, Brouwer J, Delewi R, et al.  Anticoagulation with or without Clopidogrel after Transcatheter Aortic-Valve Implantation.Continue reading “Popular, I know about POPular TAVI”

GUIDE-IT Guidance with Dr. Groo

Dr. Vicki Groo discusses the GUIDE-IT trial and medication titration in the heart failure with reduced ejection fraction (HFrEF) population. 0:00-0:40: Intro 0:40-1:27: Introduction of Dr. Vicki Groo 1:28-4:55: Introduction of GUIDE-IT trial and secondary analysis 4:56-7:56: Vicki’s Overall Thoughts 7:57-9:07: Approach to medication titration 9:08-10:31: What about newer HFrEF therapies? 10:32-12:09: Patient Education 12:10-14:07:Continue reading “GUIDE-IT Guidance with Dr. Groo”

The VICTORIA Trial

Dr. Kristen Pogue discusses the VICTORIA trial. Episode Breakdown: 0:00-0:40: Intro 0:41-1:36: Introduction of Dr. Kristen Pogue 1:37-5:42: VICTORIA trial overview 5:43-8:18: Kristen’s initial thoughts 8:19-9:44: VICTORIA and PARADIGM-HF 9:45-12:17: How does this fit with DAPA-HF results? 12:18-14:14: Vericiguat in the Black population 14:15-15:45: Final thoughts 15:46-16:32: Closing References: VICTORIA Trial: Armstrong PW, Pieske B,Continue reading “The VICTORIA Trial”

The Cold Truth of COLCOT

Dr. Toby Trujillo discusses the COLCOT trial. Episode Breakdown: 0:00-0:40: Intro 0:41-1:30: Introduction of Dr. Toby Trujillo 1:31-3:56: COLCOT overview 3:57-4:50: Toby’s initial thoughts 4:51-6:08: Anti-inflammatory agents 6:09-7:09: Pneumonia? 7:10-8:29: Baseline Management of Patients 8:30-10:15: Who is the niche colchicine patient? 10:16-12:05: Drug burden and cost 12:06-13:03: Follow-up period 13:04-13:59: Final thoughts 14:00-14:44: Closing References:Continue reading “The Cold Truth of COLCOT”

Return of the Lytics with Dr. Danielle Blais

Tune in as Dr. Danielle Blais discusses everything lytics. References: https://www.acc.org/latest-in-cardiology/articles/2020/03/18/15/07/poll-covid-19-and-interventional-cardiology Welt FGP, Shah PB, Aronow HD, et al. Catheterization Laboratory Considerations During the Coronavirus (COVID-19) Pandemic: From American College of Cardiology’s (ACC) Interventional Council and the Society of Cardiovascular Angiography and Intervention (SCAI).  J Am Coll Cardiol  2020; DOI: 10.1016/j.jacc.2020.03.021 ISIS-2 Collaborative Group. Randomised TrialContinue reading “Return of the Lytics with Dr. Danielle Blais”

Chlorthalidone vs. Hydrochlorothiazide: The Debate That Never Ends

Dr. Karen McConnell discusses a recent trial comparing chlorthalidone vs. hydrochlorothiazide for the treatment of hypertension. 0:00-0:40: Intro0:41-1:51: Introduction of Dr. Karen McConnell1:52-6:19: Trial overview6:20-9:15: Karen’s Overall Thoughts9:16-10:13: Trial Design 10:14-10:54: Side Effect Differences10:55-12:36: Choosing Between Chlorthalidone and HCTZ12:37-14:03: Final Thoughts14:04-14:49: Closing References: Hripcsak G, Suchard MA, Shea S, et al. Comparison of Cardiovascular and SafetyContinue reading “Chlorthalidone vs. Hydrochlorothiazide: The Debate That Never Ends”

Crushing ISCHEMIA with Dr. Barbara Wiggins

Dr. Barbara Wiggins joins the CardioScripts team to talk about the ISCHEMIA trial. 0:00-0:40: Intro0:41-1:22: Introduction of Dr. Barbara Wiggins1:23-5:26: Introduction of ISCHEMIA5:27-6:37: Barbara’s Overall Thoughts6:38-7:33: What does the ISCHEMIA trial add to COURAGE?7:34-8:27: Patient Baseline Medication Regimens8:28-10:42: ISCHEMIA Questions10:43-11:51: ISCHEMIA Implications for Pharmacy Practice11:52-14:03: Barbara’s Final Thoughts14:04-14:48: Closing References: ISCHEMIA Trial: The ISCHEMIA TrialContinue reading “Crushing ISCHEMIA with Dr. Barbara Wiggins”

PIONEERing HF Care with Dr. Van Tassell

Dr. Ben Van Tassell discusses sacubatril-valsartan and the PIONEER-HF trial. 0:00-0:40: Intro0:41-1:14: Introduction of Dr. Ben Van Tassell1:15-4:00: Introduction of PIONEER-HF4:01-5:22: Ben’s Initial Thoughts5:23-6:40: Sacubatril-valsartan right out of the gate?6:41-7:50: Thoughts on open-label expansion trial7:51-11:12: Role of NT-proBNP as a surrogate endpoint11:13-14:17: Cost considerations with sacubitril-valsartan14:18-15:33: Patient follow-up in a real-world setting15:34-16:13: Closing References: PIONEER-HF:Continue reading “PIONEERing HF Care with Dr. Van Tassell”